Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

✍ Scribed by Koeppen, H.; Yu, W.; Zha, J.; Pandita, A.; Penuel, E.; Rangell, L.; Raja, R.; Mohan, S.; Patel, R.; Desai, R.; Fu, L.; Do, A.; Parab, V.; Xia, X.; Januario, T.; Louie, S. G.; Filvaroff, E.; Shames, D. S.; Wistuba, I.; Lipkind, M.; Huang, J.; Lazarov, M.; Ramakrishnan, V.; Amler, L.; Phan, S.-C.; Patel, P.; Peterson, A.; Yauch, R. L.

• Book ID: 126721085
• Publisher: American Association for Cancer Research
• Year: 2014
• Tongue: English
• Weight: 677 KB
• Volume: 20
• Category: Article
• ISSN: 1078-0432
• DOI: 10.1158/1078-0432.CCR-13-1836